{"sequenceId":"845363544088","id":"34207155269","language":"English","title":"Idera Pharmaceuticals (IDRA) Rating Increased to Hold at ValuEngine","content":"ValuEngine upgraded shares of Idera Pharmaceuticals (NASDAQ:IDRA) from a sell rating to a hold rating in a report released on Friday, May 18th.    Several other analysts also recently issued reports on IDRA. HC Wainwright  set a $4.00 price objective on shares of Idera Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, January 23rd. BidaskClub cut Idera Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday, January 25th. Finally, Zacks Investment Research cut Idera Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, March 9th. One equities research analyst  has rated the stock with a sell rating, one  has issued  a hold rating, two have assigned  a buy rating and one  has given a strong buy rating to the stock. The company currently has an average rating of Buy and an average price target of $3.33.    Get Idera Pharmaceuticals alerts:      Shares of Idera Pharmaceuticals traded down $0.04, hitting $2.01, during trading hours on Friday, Marketbeat reports. 2,082,665 shares of the company were exchanged, compared to its average volume of 1,572,760. The firm has a market cap of $436.80 million, a P/E ratio of -4.79 and a beta of 2.29. Idera Pharmaceuticals has a 1 year low of $1.32 and a 1 year high of $2.87.      Idera Pharmaceuticals (NASDAQ:IDRA) last issued its quarterly earnings data on Wednesday, May 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). Idera Pharmaceuticals had a negative net margin of 9,117.07% and a negative return on equity of 82.70%. The firm had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.17 million.  equities analysts expect that  Idera Pharmaceuticals will post -0.39 earnings per share for the current year.    Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of  Idera Pharmaceuticals by 38.1% during the 4th quarter. BlackRock Inc. now owns 9,005,243 shares of the biotechnology company’s stock valued at $19,000,000 after buying an additional 2,486,098 shares during the last quarter.  Millennium Management LLC lifted its stake in  Idera Pharmaceuticals by 25.8% during the first quarter. Millennium Management LLC now owns 4,848,557 shares of the biotechnology company’s stock worth $8,921,000 after purchasing an additional 994,232 shares during the last quarter.  Artal Group S.A. bought a new position in  Idera Pharmaceuticals during the first quarter worth $5,060,000.  Bain Capital Public Equity Management LLC bought a new position in  Idera Pharmaceuticals during the fourth quarter worth $4,816,000.  Finally, Geode Capital Management LLC lifted its stake in  Idera Pharmaceuticals by 27.8% during the fourth quarter. Geode Capital Management LLC now owns 1,276,263 shares of the biotechnology company’s stock worth $2,692,000 after purchasing an additional 277,566 shares during the last quarter. Institutional investors own  42.47% of the company’s stock.    Idera Pharmaceuticals Company Profile    Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology.    To view ValuEngine’s full report, visit ValuEngine’s official website .","contentWithMarkup":"ValuEngine upgraded shares of Idera Pharmaceuticals (NASDAQ:IDRA) from a sell rating to a hold rating in a report released on Friday, May 18th.    Several other analysts also recently issued reports on IDRA. HC Wainwright  set a $4.00 price objective on shares of Idera Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, January 23rd. BidaskClub cut Idera Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday, January 25th. Finally, Zacks Investment Research cut Idera Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, March 9th. One equities research analyst  has rated the stock with a sell rating, one  has issued  a hold rating, two have assigned  a buy rating and one  has given a strong buy rating to the stock. The company currently has an average rating of Buy and an average price target of $3.33.    Get Idera Pharmaceuticals alerts:      Shares of Idera Pharmaceuticals traded down $0.04, hitting $2.01, during trading hours on Friday, Marketbeat reports. 2,082,665 shares of the company were exchanged, compared to its average volume of 1,572,760. The firm has a market cap of $436.80 million, a P/E ratio of -4.79 and a beta of 2.29. Idera Pharmaceuticals has a 1 year low of $1.32 and a 1 year high of $2.87.      Idera Pharmaceuticals (NASDAQ:IDRA) last issued its quarterly earnings data on Wednesday, May 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). Idera Pharmaceuticals had a negative net margin of 9,117.07% and a negative return on equity of 82.70%. The firm had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.17 million.  equities analysts expect that  Idera Pharmaceuticals will post -0.39 earnings per share for the current year.    Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of  Idera Pharmaceuticals by 38.1% during the 4th quarter. BlackRock Inc. now owns 9,005,243 shares of the biotechnology company’s stock valued at $19,000,000 after buying an additional 2,486,098 shares during the last quarter.  Millennium Management LLC lifted its stake in  Idera Pharmaceuticals by 25.8% during the first quarter. Millennium Management LLC now owns 4,848,557 shares of the biotechnology company’s stock worth $8,921,000 after purchasing an additional 994,232 shares during the last quarter.  Artal Group S.A. bought a new position in  Idera Pharmaceuticals during the first quarter worth $5,060,000.  Bain Capital Public Equity Management LLC bought a new position in  Idera Pharmaceuticals during the fourth quarter worth $4,816,000.  Finally, Geode Capital Management LLC lifted its stake in  Idera Pharmaceuticals by 27.8% during the fourth quarter. Geode Capital Management LLC now owns 1,276,263 shares of the biotechnology company’s stock worth $2,692,000 after purchasing an additional 277,566 shares during the last quarter. Institutional investors own  42.47% of the company’s stock.    Idera Pharmaceuticals Company Profile    Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology.    To view ValuEngine’s full report, visit ValuEngine’s official website .","tags":[],"publishedDate":"2018-06-03T03:31:00Z","harvestDate":"2018-06-02T21:35:22Z","estimatedPublishedDate":"2018-06-02T21:35:22Z","url":"http://ct.moreover.com/?a=34207155269&p=1u0&v=1&x=tJme52YVwyC5xt34WfAuAQ","originalUrl":"https://ledgergazette.com/2018/06/02/idera-pharmaceuticals-idra-stock-rating-upgraded-by-valuengine-2.html","outboundUrls":["https://www.marketbeat.com/logos/idera-pharmaceuticals-inc-logo.png","http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=IDRA","http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","https://www.marketbeat.com/","http://www.valuengine.com/rep/order_report?pid=64&srchfor=IDRA"],"wordCount":"512","dataFormat":"text","duplicateGroupId":"34207155269","media":{"audio":[],"images":[],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Biotech news","group":"Industry"},{"name":"Pharma industry news","group":"Industry"},{"name":"Business latest","group":"Business"}],"companies":[{"name":"Idera Pharmaceuticals Inc","symbol":"IDRA","exchange":"NAS","isin":"US45168K3068","titleCount":1,"contentCount":17,"primary":true},{"name":"Idera Pharmaceuticals Inc","symbol":"HXXA","exchange":"STU","isin":"US45168K3068","titleCount":1,"contentCount":17,"primary":true},{"name":"Idera Pharmaceuticals Inc","symbol":"HXXA","exchange":"BER","isin":"US45168K3068","titleCount":1,"contentCount":17,"primary":true},{"name":"Idera Pharmaceuticals Inc","symbol":"HXXA","exchange":"FRA","isin":"US45168K3068","titleCount":1,"contentCount":17,"primary":true},{"name":"BlackRock Inc","symbol":"BLQA","exchange":"STU","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLQA","exchange":"MUN","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLK","exchange":"MEX","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLQA","exchange":"FRA","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLQA","exchange":"BER","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLK","exchange":"SWX","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLK","exchange":"NYS","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLAK34","exchange":"BSP","isin":"BRBLAKBDR003","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"0QZZ","exchange":"LTS","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLQA","exchange":"ETR","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLK","exchange":"WBO","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TOC","exchange":"FRA","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TOC","exchange":"MUN","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TRI","exchange":"NYS","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TRI","exchange":"TSE","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TRI.PR.B","exchange":"TSE","isin":"CA8849033037","titleCount":0,"contentCount":1,"primary":false}],"author":{"name":"Sebastian Weber","publishingPlatform":{}},"licenses":[{"name":"Publicly Available"}],"source":{"name":"Ledger Gazette","homeUrl":"https://ledgergazette.com","category":"Trade","editorialRank":"3","industry":"Banking & Finance","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"599564993","name":"Ledger Gazette","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"1137"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Professional","Business"],"genre":"General"}},"es_id":86991817}